PMC6398997_01
FDG-PET/CT showed a primary lesion at the dorsum of the left foot (SUV: 13.6), extensor muscles, and subcutaneous fat tissue. CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
10-1055-s-0039-1678709-i1800040cr-1.jpg
PMC6398997_01_10-1055-s-0039-1678709-i1800040cr-1.jpg
FI1800040cr-1
A metastatic lymph node, measuring 2 cm in diameter, is noted (SUVmax: 9.1) ( Figs. 1 and 2 ).
FDG-PET/CT showed a mass filling the uterine cavity and metastatic lymph node (SUV: 9.1). CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
10-1055-s-0039-1678709-i1800040cr-2.jpg
PMC6398997_01_10-1055-s-0039-1678709-i1800040cr-2.jpg
FI1800040cr-2
A metastatic lymph node, measuring 2 cm in diameter, is noted (SUVmax: 9.1) ( Figs. 1 and 2 ).
Immunohistochemical staining revealed positive (a) CD20, (b) CD79a, (c) above marked immunoblast, below centroblast cell, bcl-6 (+) on uterine specimen (HE x400), and (d) immunoblast cell in cutaneous biopsy (HE x400). HE, hematoxylin and eosin.
10-1055-s-0039-1678709-i1800040cr-3.jpg
PMC6398997_01_10-1055-s-0039-1678709-i1800040cr-3.jpg
FI1800040cr-3
DLBCL. DLBCL-leg was diagnosed when MUM1 (+), CD20 (+), CD3 (-), CD5 (-), CD38 focal (+), CD79a (+), c-myc 20 to 30% (+), bcl-2 (+), bcl-6 (+), and CD10 (-) were evaluated with clinical findings ( Fig. 3a - d ).The uterine tumor was diagnosed as stage IEA DLBCL according to the Lugano modification of
Complete remission after immunochemotherapy was showed on uterine and crural region on FDG-PET/CT (SUV: 2). CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
10-1055-s-0039-1678709-i1800040cr-4.jpg
PMC6398997_01_10-1055-s-0039-1678709-i1800040cr-4.jpg
FI1800040cr-4
After six courses of chemotherapy, PET-CT was performed and it demonstrated a residual mass extending to subcutaneous tissue and muscles of dorsum of left foot (SUVmax: 2.0) ( Fig. 4 ). A skin biopsy was performed.